Rep. Gilbert Ray Cisneros, Jr. Acquires Shares of Insulet Corporation (NASDAQ:PODD)

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Insulet Corporation (NASDAQ:PODD). In a filing disclosed on November 10th, the Representative disclosed that they had bought between $1,001 and $15,000 in Insulet stock on October 20th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 11/2/2026.
• Purchased $1,001 – $15,000 in shares of argenex (NASDAQ:ARGX) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Illumina (NASDAQ:ILMN) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Revvity (NYSE:RVTY) on 10/27/2026.
• Sold $15,001 – $50,000 in shares of PTC (NASDAQ:PTC) on 10/27/2026.
• Purchased $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 10/27/2026.
• Purchased $1,001 – $15,000 in shares of MACOM Technology Solutions (NASDAQ:MTSI) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Micron Solutions (OTCMKTS:MICR) on 10/21/2026.
• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/21/2026.
• Purchased $1,001 – $15,000 in shares of ServiceNow (NYSE:NOW) on 10/21/2026.

Insulet Price Performance

PODD stock traded down $0.74 during mid-day trading on Thursday, hitting $149.29. The company had a trading volume of 745,601 shares, compared to its average volume of 1,392,376. The company has a quick ratio of 1.83, a current ratio of 2.51 and a debt-to-equity ratio of 0.60. The company has a market capitalization of $10.36 billion, a price-to-earnings ratio of 24.31, a P/E/G ratio of 1.13 and a beta of 1.06. Insulet Corporation has a 12-month low of $126.40 and a 12-month high of $354.88. The company has a 50-day moving average price of $142.08 and a 200 day moving average price of $174.71.

Insulet (NASDAQ:PODD) last announced its earnings results on Wednesday, November 4th. The medical instruments supplier reported $1.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.59 by $0.40. The firm had revenue of $842.00 million for the quarter, compared to analysts’ expectations of $832.63 million. Insulet had a net margin of 13.44% and a return on equity of 31.76%. The business’s revenue was up 19.2% compared to the same quarter last year. During the same period in the prior year, the company earned $1.24 EPS. On average, research analysts anticipate that Insulet Corporation will post 6.75 earnings per share for the current year.

Institutional Investors Weigh In On Insulet

Several institutional investors and hedge funds have recently added to or reduced their stakes in PODD. AlphaGrep UK Ltd increased its holdings in shares of Insulet by 25.5% in the third quarter. AlphaGrep UK Ltd now owns 6,941 shares of the medical instruments supplier’s stock valued at $906,000 after purchasing an additional 1,410 shares during the last quarter. First Trust Advisors LP lifted its stake in Insulet by 114.7% during the third quarter. First Trust Advisors LP now owns 13,004 shares of the medical instruments supplier’s stock worth $1,697,000 after purchasing an additional 6,946 shares in the last quarter. Advisors Asset Management Inc. purchased a new position in Insulet during the 3rd quarter valued at about $77,000. GW&K Investment Management LLC grew its holdings in shares of Insulet by 74.6% in the third quarter. GW&K Investment Management LLC now owns 695 shares of the medical instruments supplier’s stock valued at $91,000 after purchasing an additional 297 shares in the last quarter. Finally, Private Wealth Asset Management LLC acquired a new position in Insulet during the 3rd quarter worth $266,000.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Royal Bank Of Canada raised their price target on shares of Insulet from $160.00 to $180.00 and gave the stock an “outperform” rating in a research note on Thursday, November 5th. Oppenheimer lowered Insulet from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 5th. Benchmark decreased their target price on shares of Insulet from $250.00 to $185.00 and set a “buy” rating for the company in a research report on Thursday, August 6th. Stifel Nicolaus decreased their price objective on shares of Insulet from $225.00 to $180.00 and set a “buy” rating for the company in a research report on Thursday, August 6th. Finally, Robert W. Baird set a $175.00 price objective on Insulet in a research note on Thursday, August 6th. Twelve analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Insulet currently has a consensus rating of “Hold” and a consensus target price of $185.67.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Insulet Company Profile

Insulet Corporation is a medical device company focused on insulin delivery for people with diabetes. Founded in 2000, the company developed the Omnipod platform, which delivers insulin through a small, wearable pod without the tubing used by many traditional insulin pumps. Its products include Omnipod DASH and Omnipod 5, an automated insulin delivery system that can adjust insulin delivery based on glucose readings from compatible continuous glucose monitors. Insulet also provides related controllers, mobile app features, supplies and customer support.